Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F3 | P13726 | 3/20 | 0.86 |
| ▸ | GSK3B | P49841 | 3/20 | 0.73 |
| ▸ | BACE1 | P56817 | 2/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | ATM | Q13315 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.71 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.71 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.71 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.71 |
| ▸ | BCHE | P06276 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.71 |
| ▸ | RELA | Q04206 | 1/20 | 0.71 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599044 | 1.00 | F3 (0.86) | F3GSK3BBACE1THRBATM | |
| SCHEMBL2744101 | 0.93 | F3 (1.00) | F3GSK3BBACE1THRBATM | |
| SCHEMBL14331811 | 0.93 | F3 (1.00) | F3GSK3BBACE1THRBATM | |
| SCHEMBL2744098 | 0.93 | F3 (1.00) | F3GSK3BBACE1THRBATM | |
| SCHEMBL17837284 | 0.91 | F3 (0.96) | F3GSK3BBACE1THRBATM | |
| SCHEMBL18699288 | 0.90 | GSK3B (0.91) | F3GSK3BBACE1THRBATM | |
| 4-Methoxycinnamic Acid SCHEMBL28105146 | 0.89 | THRB (0.89) | F3GSK3BBACE1THRBATM | |
| SCHEMBL10467108 | 0.88 | F3 (0.83) | F3GSK3BBACE1THRBATM | |
| SCHEMBL10467105 | 0.88 | F3 (0.83) | F3GSK3BBACE1THRBATM | |
| SCHEMBL10467112 | 0.88 | F3 (0.83) | F3GSK3BBACE1THRBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| EP-3113767-B1 | MTOR-INDEPENDENT ACTIVATOR OF TFEB FOR AUTOPHAGY ENHANCEMENT AND USES THEREOF | UNIV HONG KONG BAPTIST UNIV (CN) | 2020-12-09 | — | — | EP | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | ANKH LIFE SCIENCES LIMITED (IE) | 2019-08-01 | — | — | US | disclosed |
| US-20150250741-A1 | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2015-09-10 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | F3 4264/4885GSK3B 2563/4885BACE1 1295/4885 |
| US-20190231756-A1 | THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF | INMT, HNMT, COMT | F3 4252/4885GSK3B 462/4885BACE1 500/4885 |
| US-20150250741-A1 | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | TFEB, SQSTM1, ATG7 | F3 2784/4885GSK3B 1696/4885BACE1 1360/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | F3 4781/4885GSK3B 2812/4885BACE1 750/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | F3 4264/4885GSK3B 2563/4885BACE1 1295/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | F3 4781/4885GSK3B 2812/4885BACE1 750/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | F3 4264/4885GSK3B 2563/4885BACE1 1295/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | F3 4252/4885GSK3B 462/4885BACE1 500/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | F3 4264/4885GSK3B 2563/4885BACE1 1295/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | F3 4264/4885GSK3B 2563/4885BACE1 1295/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | F3 4252/4885GSK3B 462/4885BACE1 500/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | F3 3835/4885GSK3B 3461/4885BACE1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.